EMERGENTEC BIODEVELOPMENT GMBH
Gersthofer Strasse 29-31 – Vienna – 1180
VAT: ATU53574706
Complicit EU Projects
Within the Horizon 2020 (2014-2020) framework, EMERGENTEC BIODEVELOPMENT GMBH has received € 898,775.0 for its participation in a total of 1 project(s) with a total cost of € 5,968,480.
| Start (YYYYMMDD) | Project ID | Project Name | Themes | End (YYYYMMDD) | Role | EC Contribution | Total Cost | IL Participation | Total Participation | CORDIS Link |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-01-01 | 848011 | DC-ren | diabetic nephropathy · pharmaceutical drugs · pathophysiology · pathology · kidney diseases | 2024-12-31 | participant | € 898,775.0 | € 5,968,480 | 1 | 8 | CORDIS ↪ |
EMERGENTEC BIODEVELOPMENT GMBH did not participate in complicit projects under Horizon Europe (2021-2027).
Within the FP7 (2007-2013) framework, EMERGENTEC BIODEVELOPMENT GMBH has received € 1,047,366.0 for its participation in a total of 2 project(s) with a total cost of € 19,708,540.
| Start (YYYYMMDD) | Project ID | Project Name | Themes | End (YYYYMMDD) | Role | EC Contribution | Total Cost | IL Participation | Total Participation | CORDIS Link |
|---|---|---|---|---|---|---|---|---|---|---|
| 2012-01-01 | 279113 | OCTIPS | mortality · surgery · transition metals · oncology | 2015-12-31 | participant | € 230,986.0 | € 3,964,946 | 1 | 11 | CORDIS ↪ |
| 2010-01-01 | 241544 | SYSKID | epidemiology · pathophysiology · kidney diseases | 2014-12-31 | coordinator | € 816,380.0 | € 15,743,594 | 1 | 29 | CORDIS ↪ |